<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02123576</url>
  </required_header>
  <id_info>
    <org_study_id>17365</org_study_id>
    <nct_id>NCT02123576</nct_id>
  </id_info>
  <brief_title>Treatment of Type I Hepatorenal Syndrome (HRS) With Pentoxyfylline</brief_title>
  <official_title>Treatment of Type I Hepatorenal Syndrome (HRS) With Pentoxyfylline: A Placebo Controlled, Blinded Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Patrick Northup, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pentoxyfylline therapy in addition to the standard of care of albumin, midodrine and
      octreotide therapy is superior to the standard of care alone in the treatment of Type I
      hepatorenal syndrome in the first 14 days of hospitalization.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Each hospitalized subject will undergo pre-dosing screening with review of his or her history
      and physical exam from the day of enrollment and safety assessment to ensure no
      contraindication to use of PTX. Type I HRS will be defined according to the criteria put
      forth by the American Association for the Study of Liver Disease as (1) cirrhosis with
      ascites; (2) serum creatinine greater than 1.5 mg/dL; (3) no improvement of serum creatinine
      (decrease to a level of 1.5 mg/dL or less) after at least two days with diuretic withdrawal
      and volume expansion with albumin; (4) absence of shock; (5) no current or recent treatment
      with nephrotoxic drugs; and (6) absence of parenchymal kidney disease as indicated by
      proteinuria &gt;500 mg/day, microhematuria (&gt;50 red blood cells per high power field), and/or
      abnormal renal ultrasonography. Baseline testing will be obtained from hospitalization
      records, including but not limited to chemistry panel, liver function testing, urinalysis,
      urine electrolytes, coagulation studies, blood cultures, chest x-ray, diagnostic
      paracentesis, abdominal ultrasound with Doppler.

      Subjects will take either placebo three times a day or pentoxyfylline 400mg three times a day
      or 400mg twice a day for eGFR 10-50 and 400mg once a day for eGFR &lt;10 for 90 days in addition
      to standard AMO therapy. Treatment will be continued for 14 days unless a study endpoint has
      been reached at which time either PTX or placebo will be stopped
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Poor enrollment of study population
  </why_stopped>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">December 31, 2017</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment success</measure>
    <time_frame>14 days</time_frame>
    <description>We define this as a decrease in serum creatinine level to &lt;1.5 mg/dL without dialysis or death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in serum creatinine from baseline</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment failure</measure>
    <time_frame>Day14</time_frame>
    <description>Defined as creatinine level above baseline value after day 7, dialysis or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combined increase of treatment success and &quot;partial response</measure>
    <time_frame>14 days</time_frame>
    <description>We define as serum creatinine level decreased by &gt;50% from baseline but not to &lt;1.5 mg/dL, without dialysis or HRS recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transplant free survival</measure>
    <time_frame>day 30 and 180</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite survival index</measure>
    <time_frame>day 30 and 180</time_frame>
    <description>.This will be the combination of transplant free survival and those patients who received liver transplant</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Hepatorenal Syndrome</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pentoxyfylline 400mg three times a day or 400mg twice a day for eGFR 10-50 and 400mg once a day for eGFR &lt;10 for 90 days in addition to standard AMO therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This is a standard placebo pill.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pentoxyfylline</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMO Therapy</intervention_name>
    <description>Albumin, midodrine and octreotide therapy (standard of care for HRS)</description>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hospitalized patients with acute or chronic liver disease

          -  Type I HRS

          -  Aged greater than or equal to 18

          -  Non-pregnant

        Exclusion Criteria:

          -  Allergy or hypersensitivity to PTX or intolerance to methylxanthines (e.g. caffeine,
             theophylline)

          -  Concurrent use of nephrotoxic drugs

          -  Age less than 18

          -  Pregnancy

          -  Uncontrolled bacterial infection

          -  Renal parenchymal disease (e.g. acute tubular necrosis, glomerular disease,
             interstitial nephritis and urinary obstruction)

          -  Shock

          -  TNF alpha antagonist use

          -  Subject is institutionalized or a prisoner

          -  Recent cerebral or retinal hemorrhage (contraindication to PTX)

          -  Severe or poorly controlled cardiovascular disease as determined by the principal
             investigator to hinder the ability to adhere to study protocols
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick G Northup, MD MHS</last_name>
    <role>Study Director</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jonathan G Stine, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Morgan TR, McClain CJ. Pentoxifylline and alcoholic hepatitis. Gastroenterology. 2000 Dec;119(6):1787-91. Review.</citation>
    <PMID>11113103</PMID>
  </reference>
  <reference>
    <citation>Angeli P. Î²-blockers and refractory ascites in cirrhosis: the message of a team of true scientists. J Hepatol. 2011 Oct;55(4):743-4. doi: 10.1016/j.jhep.2011.02.026. Epub 2011 Mar 10.</citation>
    <PMID>21396970</PMID>
  </reference>
  <reference>
    <citation>Lott JP. Renal failure in cirrhosis. N Engl J Med. 2010 Jan 7;362(1):79; author reply 80-1. doi: 10.1056/NEJMc0910190.</citation>
    <PMID>20054052</PMID>
  </reference>
  <reference>
    <citation>Spring FA, Dalchau R, Daniels GL, Mallinson G, Judson PA, Parsons SF, Fabre JW, Anstee DJ. The Ina and Inb blood group antigens are located on a glycoprotein of 80,000 MW (the CDw44 glycoprotein) whose expression is influenced by the In(Lu) gene. Immunology. 1988 May;64(1):37-43.</citation>
    <PMID>2454887</PMID>
  </reference>
  <reference>
    <citation>Fallon E, Ehrenwald E, Nazarian GK, Smith CI. TIPS with a polytetrafluoroethylene-lined stent graft and associated haemolytic anaemia. Gut. 2008 Aug;57(8):1180-1.</citation>
    <PMID>18628385</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2014</study_first_submitted>
  <study_first_submitted_qc>April 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2014</study_first_posted>
  <last_update_submitted>May 1, 2017</last_update_submitted>
  <last_update_submitted_qc>May 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>Patrick Northup, MD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Hepatorenal syndrome</keyword>
  <keyword>Renal failure</keyword>
  <keyword>Pentoxyfylline</keyword>
  <keyword>Liver transplantation</keyword>
  <keyword>Cirrhosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Hepatorenal Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pentoxifylline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

